Bronchopulmonary Dysplasia Clinical Trial
Official title:
Antibiotic Effects on the Developing Microbiome, Metabolome and Morbidities in Preterm Neonates
Verified date | April 2020 |
Source | University of Florida |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Prolonged antibiotic use in preterm neonates has significant consequences on the developing
intestinal microbiome, metabolome and host response, predisposing the neonate to various
major morbidities, including necrotizing enterocolitis (NEC), late-onset sepsis,
bronchopulmonary dysplasia (BPD), and mortality.
The hypothesis is that early and prolonged antibiotic use in preterm neonates has significant
consequences on the developing intestinal microbiome, metabolome and host response,
predisposing the neonate to various major morbidities. It is possible that the effect of this
widespread antibiotic use outweighs the potential benefits. This study will randomize preterm
infants born at less than 33 weeks gestation to either pre-emptive antibiotics or
no-pre-emptive antibiotics.
The purpose of this research is to evaluate the risks and benefits of current practice to
determine optimal levels of antibiotic use that protects the babies from infection with
minimal effect on the microbiome and subsequent adverse outcomes related to overuse of
antibiotics.
Status | Completed |
Enrollment | 186 |
Est. completion date | September 11, 2019 |
Est. primary completion date | September 11, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 23 Weeks to 33 Weeks |
Eligibility |
Inclusion Criteria: - All infants less than 33 weeks gestation. Exclusion Criteria: - Infants who are non-viable at birth. |
Country | Name | City | State |
---|---|---|---|
United States | University of Florida | Gainesville | Florida |
Lead Sponsor | Collaborator |
---|---|
University of Florida | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Society for Pediatric Dermatology |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rates of composite morbidities and mortality, including necrotizing enterocolitis(NEC), late onset sepsis (LOS), bronchopulmonary dysplasia (BPD) and death | Enrolled subjects' medical record will be reviewed to determine the association between antibiotic administration and the components of the composite outcome | Until discharge from the NICU, up to 1 year | |
Secondary | Rates of bacteremia | Enrolled subjects' medical record will be reviewed to determine the association between antibiotic administration and the development of bacteremia after the first week of life. | Until discharge from the NICU, up to 1 year | |
Secondary | Microbiota 16s ribosomal ribonucleic acid (rRNA) metagenomic sequencing | Pacific BioSciences or Illumina sequencing will be done and the data analyzed using metagenomics Rapid Annotation using Subsystem Technology (MG-RAST). | Until discharge from the NICU, up to 1 year | |
Secondary | Microbial diversity analysis | Microbial diversity is assessed using Chao1, Shannon, and ordination methods implemented using a software program called phyloseq package in R.42 Chao1 estimates the species richness for each sample, while the Shannon Index scores richness and abundance, though is not sufficient in assessing overall microbiome differences. Detrended Correspondence Analysis (DCA), a multivariate statistical method, will be applied to detect overall microbiome differences. Adonis methods were used to attribute additional variables' contribution to microbial variance. | Until discharge from the NICU, up to 1 year | |
Secondary | Calprotectin (microgram per gram) levels in stool | Calprotectin levels will be analyzed using an ELISA kit. | Until discharge from the NICU, up to 1 year | |
Secondary | Metabolomic analysis (microMol per gram) in gastric aspirate, stool, and breast milk | Metabolites as biomarkers of microbial-host metabolism will be identified by nuclear magnetic resonance and mass spectrometry. Levels of vitamins(microMol per gram), polyphenols(microMol per gram), cholesterol (microMol per gram), and short chain fatty acids(microMol per gram) will be measured. | Until discharge from the NICU, up to 1 year | |
Secondary | S1000A12 (microgram per gram) in stool | S1000A12 levels will be analyzed using an ELISA kit. | Until discharge from the NICU, up to 1 year | |
Secondary | Intraleukin-6 (micrograms per gram) in stool | Intraleukin-6 values will be assessed using multiplex technologies. | Until discharge from the NICU, up to 1 year | |
Secondary | Intraleukin-8 (micrograms per gram) in stool | Intraleukin-8 values will be assessed using multiplex technologies. | Until discharge from the NICU, up to 1 year | |
Secondary | Intraleukin-10 (micrograms per gram) in stool | Intraleukin-10 values will be assessed using multiplex technologies. | Until discharge from the NICU, up to 1 year | |
Secondary | Rates of bronchopulmonary dysplasia (BPD) | Enrolled subjects' medical record will be reviewed to determine the association between antibiotic administration and diagnosis of BPD. | Until discharge from the NICU, up to 1 year | |
Secondary | Rates of spontaneous ileal perforation | Enrolled subjects' medical record will be reviewed to determine the association between antibiotic administration and spontaneous ileal perforation | Until discharge from the NICU, up to 1 year | |
Secondary | Rates of intraventricular hemorrhage | Enrolled subjects' medical record will be reviewed to determine the association between antibiotic administration and intraventricular hemorrhage | Until discharge from the NICU, up to 1 year | |
Secondary | Rates of necrotizing enterocolitis (NEC) | Enrolled subjects' medical record will be reviewed to determine the association between antibiotic administration and intraventricular hemorrhage | Until discharge from the NICU, up to 1 year | |
Secondary | Rates of retinopathy of prematurity | Enrolled subjects' medical record will be reviewed to determine the association | Until discharge from the NICU, up to 1 year | |
Secondary | Rates of periventricular leukomalacia | Enrolled subjects' medical record will be reviewed to determine the association | Until discharge from the NICU, up to 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04506619 -
Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants
|
||
Completed |
NCT04936477 -
Ventilation-perfusion (V/Q) Ratio and Alveolar Surface Area in Preterm Infants
|
N/A | |
Recruiting |
NCT05285345 -
Implementation of a Consensus-Based Discharge Protocol for Preterm Infants With Lung Disease
|
||
Completed |
NCT03649932 -
Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing
|
Phase 1 | |
Terminated |
NCT02524249 -
Early Versus Late Caffeine for ELBW Newborns
|
N/A | |
Completed |
NCT02249143 -
Duration of Continuous Positive Airway Pressure and Pulmonary Function Testing in Preterm Infants
|
N/A | |
Active, not recruiting |
NCT01632475 -
Follow-Up Study of Safety and Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia
|
||
Completed |
NCT01460576 -
Improving Prematurity-Related Respiratory Outcomes at Vanderbilt
|
N/A | |
Unknown status |
NCT00254176 -
Cysteine Supplementation in Critically Ill Neonates
|
Phase 2/Phase 3 | |
Completed |
NCT00419588 -
Growth of Airways and Lung Tissues in Premature and Healthy Infants
|
||
Completed |
NCT00319956 -
Trial II of Lung Protection With Azithromycin in the Preterm Infant
|
Phase 2 | |
Completed |
NCT00208039 -
Pilot Trial of Surfactant Booster Prophylaxis For Ventilated Preterm Neonates
|
N/A | |
Completed |
NCT00006401 -
Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants
|
Phase 3 | |
Terminated |
NCT05030012 -
Maintaining Optimal HVNI Delivery Using Automatic Titration of Oxygen in Preterm Infants
|
N/A | |
Completed |
NCT00006058 -
Study of the Pathobiology of Bronchopulmonary Dysplasia in Newborns
|
N/A | |
Completed |
NCT00005376 -
Premature Birth and Its Sequelae in Women
|
N/A | |
Completed |
NCT00011362 -
Dexamethasone Therapy in VLBW Infants at Risk of CLD
|
Phase 3 | |
Completed |
NCT00004805 -
Study of the Effect of Four Methods of Cardiopulmonary Resuscitation Instruction on Psychosocial Response of Parents With Infants at Risk of Sudden Death
|
N/A | |
Completed |
NCT05152316 -
The Baby Lung Study
|
||
Recruiting |
NCT04821453 -
NAVA vs. CMV Crossover in Severe BPD
|
N/A |